

## Regimen Reference Order – THOR – atezolizumab

ARIA: LUNG – [atezolizumab q 21 days]

LUNG – [atezolizumab q 28 days]

**Planned Course:**      **Every 21 days until disease progression or unacceptable toxicity**  
**OR**  
**Every 28 days until disease progression or unacceptable toxicity**

**Indication for Use:**    **Non-Small Cell Lung Cancer (NSCLC) Metastatic**

**Drug Alert:**    **Immune Checkpoint Inhibitor**

**CVAD:**    **At Provider’s Discretion**

**Proceed with treatment if:**

- *ANC equal to or greater than 1.5 x 10<sup>9</sup>/L    AND    Platelets equal to or greater than 50 x 10<sup>9</sup>/L*
- *AST/ALT less than 3 times upper limit of normal*
- *Total bilirubin less than 1.5 times upper limit of normal*
- *Creatinine clearance greater than 30 mL/min*
- ❖ **Contact Physician if parameters not met**

### SEQUENCE OF MEDICATION ADMINISTRATION

#### Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

#### Treatment Regimen – THOR – atezolizumab

**Establish primary solution 500 mL of: normal saline**

Drug	Dose	CCMB Administration Guideline
atezolizumab	1200 mg (every 21 days) <b>OR</b>	IV in normal saline 250 mL <ul style="list-style-type: none"> <li>Dose 1 to be infused over 60 minutes</li> <li>Dose 2 and subsequent to be infused over 30 minutes (if first dose well tolerated)</li> </ul>
	1680 mg (every 28 days)	IV in normal saline 250 mL <ul style="list-style-type: none"> <li>Dose 1 to be infused over 60 minutes</li> <li>Dose 2 and subsequent to be infused over 30 minutes (if first dose well tolerated)</li> </ul>

**In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’**

## REQUIRED MONITORING

### All Cycles

- CBC, serum creatinine, urea, AST, ALT, total bilirubin, albumin, glucose, sodium, potassium, calcium, magnesium, phosphate and TSH as per Physician Orders
- Medical oncologist or designate (i.e. family practitioner in oncology) must assess patient for immune-mediated adverse reactions prior to each cycle
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

### Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
None required		

## DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Confirm that patient has received the CCMB Immune Checkpoint Inhibitor Medical Alert wallet card
- Reinforce to patient the immune-mediated adverse reactions and importance of reporting immediately
  - For severe symptoms, the patient should be instructed to go to the nearest emergency room. Oncologist on call should be contacted

## ADDITIONAL INFORMATION

- atezolizumab is an Immune Checkpoint Inhibitor. Consult with oncologist for immune-mediated adverse reactions; corticosteroids are often indicated